Buzzard Pharmaceuticals is a startup based in Sweden, 1 tracked investor.
Buzzard Pharmaceuticals is a startup based in Sweden. Brouky records 1 investor associated with the company.
Buzzard Pharmaceuticals is developing Isunakinra, a potent interleukin-1 (IL‑1) inhibitor — a chimeric protein that binds IL1R1 — repurposed from ophthalmology to oncology to treat solid tumours in combination with PD‑1 checkpoint inhibitors. Isunakinra was acquired from Eleven Biotherapeutics in 2017 and is currently being evaluated in Phase 1/2 trials at the Baylor Research Institute in Dallas, Texas.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.